The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans

Journal of the American College of Cardiology

Volumn 51, Issue 17, 2008, Pages 1653-1662

  Ky, Bonnie ^a   Burke, Anne ^a   Tsimikas, Sotirios ^b   Wolfe, Megan L ^a   Tadesse, Mahlet G ^a   Szapary, Philippe O ^a   Witztum, Joseph L ^b   FitzGerald, Garret A ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; ISOPROSTANE; LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPID; PLACEBO; PRAVASTATIN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHOLIPIDS; PRAVASTATIN; PYRROLES; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 43049116177     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.026     Document Type: Article

References (63)

1. Gotto Jr. A.M. Risks and benefits of continued aggressive statin therapy. Clin Cardiol 26 (2003) III3-III12
2. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45 (2005) 89-118
3. Yasunari K., Maeda K., Minami M., and Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 21 (2001) 937-942
4. Obunike J.C., Pillarisetti S., Paka L., et al. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. Arterioscler Thromb Vasc Biol 20 (2000) 111-118
5. Rikitake Y., Kawashima S., Yamashita T., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
6. Wilson S.H., Simari R.D., Best P.J., et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 21 (2001) 122-128
7. Sumi D., Hayashi T., Thakur N.K., et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155 (2001) 347-357
8. Sanguigni V., Pignatelli P., Caccese D., et al. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb Haemost 78 (2002) 796-801
9. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
10. De Caterina R., Cipollone F., Filardo F.P., et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 106 (2002) 2543-2549
11. Lee T.M., Chou T.F., and Tsai C.H. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 40 (2002) 868-874
12. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
13. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
14. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
15. Holvoet P., Donck J., Landeloos M., et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76 (1996) 663-669
16. Caslake M.J., Packard C.J., Suckling K.E., Holmes S.D., Chamberlain P., and Macphee C.H. Lipoprotein-associated phospholipase A(2), platelet activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
17. Tsimikas S., Witztum J.L., Miller E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412
18. Tsimikas S., Lau H.K., Han K.R., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109 (2004) 3164-3170
19. Tsimikas S., Bergmark C., Beyer R.W., et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 360-370
20. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcomes. Prospective results from the Bruneck study. Arterioscl Thromb Vasc Biol 27 (2007) 1788-1795
21. Lawson J.A., Li H., Rokach J., et al. Identification of two major F2 isoprostanes 8, 12-iso-and 5-epi-8, 12-iso-isoprostane F2alpha-VI, in human urine. J Biol Chem 273 (1998) 29295-29301
22. Li H., Lawson J.A., Reilly M., et al. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine. Proc Natl Acad Sci U S A 96 (1999) 13381-13386
23. Rodenburg J., Vissers M.N., Wiegman A., et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 47 (2006) 1803-1810
24. Silaste M.L., Rantala M., Alfthan G., et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol 24 (2004) 498-503
25. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25 (2005) 279-286
26. Lawson J.A., Rokach J., and FitzGerald G.A. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 274 (1999) 24441-24444
27. Patrono C., and FitzGerald G.A. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17 (1997) 2309-2315
28. Reilly M.P., Pratico D., Delanty N., et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98 (1998) 2822-2828
29. Morrow J.D., Frei V., Longmire A.W., et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332 (1995) 1198-1203
30. Reilly M., Delanty N., Lawson J.A., and FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94 (1996) 19-25
31. Practico D., Tangirala R.K., Rader D.J., Rokach J., and FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4 (1998) 1189-1192
32. Griendling K.K., and FitzGerald G.A. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 108 (2003) 2034-2040
33. Kadiiska M.B., Gladen B.C., Baird D.D., et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic Biol Med 38 (2005) 698-710
34. Mehrabi M.R., Ekmekcioglu C., Tatzber F., et al. The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 43 (1999) 492-499
35. Practico D., Iuliano L., Mauriello A., et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100 (1997) 2028-2034
36. Desideri G., Croce G., Tucci M., et al. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab 88 (2003) 5341-5347
37. Meagher E.A., Barry O.P., Lawson J.A., Rokach J., and FitzGerald G.A. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285 (2001) 1178-1182
38. Holvoet P., Davey P.C., De Keyzer D., et al. Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP-1 cells. Arterioscler Thromb Vasc Biol 26 (2006) 1558-1565
39. Holvoet P., Harris T.B., Tracy R.P., et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging and Body Composition Study. Arterioscler Thromb Vasc Biol 23 (2003) 1444-1448
40. Holvoet P., Kritchevsky S.B., Tracy R.P., et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53 (2004) 1068-1073
41. Wu T., Willett W.C., Rifai N., Shai I., Manson J.E., and Rimm E.B. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?. J Am Coll Cardiol 48 (2006) 973-979
42. Tsouli S.G., Kiortsis D.N., Lourida E.S., et al. Autoantibody titers against oxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J Lipid Res 47 (2006) 2208-2214
43. van Tits L.J., van Himbergen T.M., Lemmers H.L., de Graaf J., and Stalenhoef A.F. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185 (2006) 307-312
44. Ndrepepa G., Braun S., von Beckerath N., et al. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin Chim Acta 360 (2005) 178-186
45. Tamura A., Watanbe T., and Nasu M. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circ J 67 (2003) 816-820
46. Sasaki S., Kuwahara N., Kunitomo K., et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 89 (2002) 386-389
47. Edelstein C., Pfaffinger D., Hinman J., et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 278 (2003) 52841-52847
48. Fraley A.E., and Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 17 (2006) 502-509
49. Frostegard J., Wu R., Lemne C., Thulin T., Witztum J.L., and de Faire U. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci 105 (2003) 615-620
50. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57
51. Tsimikas S., Kiechl S., Willeit J., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47 (2006) 2219-2228
52. Tsimikas S., Aikawa M., Miller Jr. F.J., et al. Increased plasma oxidized phospholipid: apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol 27 (2007) 175-181
53. Cyrus T., Praticò D., Zhao L., et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 103 (2001) 2277-2282
54. Tsimikas S., Palinski W., and Witztum J.L. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 95-100
55. Orem C., Orem A., Uydu H.A., Celik S., Erdol C., and Kural B.V. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 13 (2002) 65-71
56. Fredrikson G.N., Hedblad B., Berglund G., et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 38 (2007) 1495-1500
57. Resch U., Tatzber F., Budinsky A., and Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 61 (2006) 262-274
58. Macphee C.H. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 1 (2001) 121-125
59. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2 high sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
60. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Eng J Med 343 (2000) 1148-1155
61. Schaefer E.J., McNamara J.R., Asztalos B.F., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95 (2005) 1025-1032
62. Albert M.A., Glynn R.J., Wolfert R.L., and Ridker P.M. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182 (2005) 193-198
63. Tsimikas S., Tsironis L.D., and Tselepis A.D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 10 (2007) 2094-2099